The treatment outcome of extrahepatic cholangiocarcinoma remains insufficient because it is difficult to obtain accurate diagnosis of tumor spreading and effective treatment agent is quite limited in spite of substantial current efforts, all of which have been unsuccessful except for gemcitabine plus cisplatin. The patient was a 60-year-old female who had developed hilar cholangiocarcinoma and ...

Introduction. Treatment of hilar cholangiocarcinoma remains one the most complicated issues surgical hepatology. As known, is resistant to chemotherapy and radiation therapy, only a option an effective way improve patient survival.The aim study was clinical outcomes patients with by evaluating efficiency various options for resection reconstructive restorative stages treatment.Methods. The invo...

Despite advances in gastrointestinal endoscopic technology, the management of malignant hilar biliary obstruction continues to be a challenge for advanced endoscopists. There has been ongoing debate regarding optimal modality both diagnostic and therapeutic interventions obstruction. Various approaches including endoscopy, interventional radiology guided surgery are available. The should includ...

BACKGROUND Unresectable intrahepatic and hilar cholangiocarcinomas carry a dismal prognosis. Systemic chemotherapy and conventional external beam radiation and brachytherapy have been used with limited success. We explored the use of stereotactic body radiotherapy (SBRT) for these patients. METHODS Patients with unresectable intrahepatic or hilar cholangiocarcinoma or those with positive marg...

BACKGROUND To examine the predictive value of tumor markers for evaluating tumor resectability in patients with hilar cholangiocarcinoma and to explore the prognostic effect of various preoperative factors on resectability in patients with potentially resectable tumors. Patients with potentially resectable tumors judged by radiologic examination were included. The receiver operating characteris...

Objective To review our surgical experience with hilar cholangiocarcinoma in the ‘‘new era.’’ Methods The medical records of 428 patients with hilar cholangiocarcinoma who underwent treatment between 2001 and 2008 at the First Department of Surgery, the Nagoya University Hospital, were retrospectively reviewed. Results Of the 428 patients, 298 (70%) underwent surgical resection (R0, n = 220; R1...

BACKGROUND Because of the rarity of hilar cholangiocarcinoma, its prognostic risk factors have not been sufficiently analyzed. This retrospective study was undertaken to evaluate various pathologic risk factors which influenced survival after curative hepatic resection or transplantation. METHODS Between 1981 and 1996, 72 patients (43 males and 29 females) with hilar cholangiocarcinoma underw...

PURPOSE To assess the feasibility and safety of percutaneous intraductal radiofrequency ablation (RFA) for unresectable Bismuth types III and IV hilar cholangiocarcinoma. RESULTS Percutaneous intraductal RFA combined with metal stent placement was successful in all patients without any technical problems; the technical success rate was 100%. Chemotherapy was administered to two patients. Afte...

OBJECTIVE To compare the experience and outcome in the management of hilar cholangiocarcinoma at one American and one Japanese medical center. SUMMARY BACKGROUND DATA Controversies surround the issues of extent of resection for hilar cholangiocarcinoma and whether the histopathology of such cancers are similar between patients treated in America and in Japan. METHODS Records were reviewed o...

Hilar cholangiocarcinoma (HCCA) is characterised by late clinical symptoms. As a consequence, most patients will not undergo surgery, and palliation is the main goal of therapy. For the few patients that undergo potentially curative surgery, the need for preoperative biliary drainage (PBD) continues to be debated and remains controversial, as there are many reports with conflicting results. For...